Workflow
宏观观察2025年第32期(总第604期):我国脑科学与脑机接口行业发展现状及建议
Zhong Guo Yin Hang·2025-09-12 06:45

Industry Overview - The brain science and brain-computer interface (BCI) industry in China is rapidly developing, with a market size projected to reach 5.58 billion yuan by 2027, growing at a compound annual growth rate (CAGR) of 26%[20] - The global BCI market is expected to grow from 1.98 billion USD in 2023 to over 6 billion USD by 2028, with a CAGR of 25%[20] Technological Development - BCI technology is categorized into three types: invasive, semi-invasive, and non-invasive, with non-invasive methods leading in application[6] - The industry is characterized by high dependence on advanced technology, requiring significant investment in research and development, with an average R&D expense ratio of 18%[37] Policy Support - The Chinese government has prioritized brain science and BCI research as a national strategic technology, with plans to establish a comprehensive technology and industry system by 2030[12] - Major cities like Beijing and Shanghai are leading in policy support and establishing research institutions to foster BCI development[14] Financial Landscape - Investment in the BCI sector has surged, with over 1,500 financing events globally, totaling nearly 10 billion USD, and China accounting for approximately 20 billion USD of that[47] - In 2024, the domestic BCI industry secured over 1.5 billion yuan in financing, with 80% directed towards invasive technology[47] Market Challenges - The industry faces challenges such as reliance on imported core components, low efficiency in technology transfer, and ethical concerns regarding safety and privacy[5] - The average gross profit margin for listed companies in the BCI sector is 33.89%, but net profit margins for downstream companies are below 10% due to market expansion pressures[37] Future Trends - The BCI industry is expected to see multi-modal integration, combining various signal acquisition methods to enhance accuracy and stability[41] - Applications in healthcare are expanding beyond existing treatments for Parkinson's and epilepsy to include conditions like Alzheimer's and ALS[42]